ipo
Stage
2016
Founded
2
Investors
About
Vir Biotechnology is a clinical-stage biotechnology company that engineers antibody-based medicines and leverages immune-system-focused platforms (including a next-generation antibody platform and the PRO-XTEN masking technology) to develop therapies for infectious diseases and oncology.
Explore Vir Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.